AbbVie Slides as U.S. Agency Questions Humira Patent
- U.S. patent office agrees to consider a challenge by Coherus
- The agency will review an AbbVie patent for the arthritis drug
This article is for subscribers only.
One of AbbVie Inc.’s patents on its top-selling arthritis drug Humira may be invalid, a U.S. agency said, agreeing to consider a challenge filed by Coherus Biosciences Inc.
Coherus has shown a “reasonable likelihood” that it will win the challenge, the Patent Trial and Appeal Board said in a decision Tuesday instituting a formal review of the patent. AbbVie shares dropped 3.5 percent, while Coherus rose 16 percent on the news.